세계의 고기능 의료용 플라스틱 시장 예측 : 원재료별, 용도별, 지역별(-2030년)

According to Stratistics MRC, the Global High Performance Medical Plastics Market is accounted for $1.15 billion in 2024 and is expected to reach $2.08 billion by 2030 growing at a CAGR of 10.4% during the forecast period. High-performance medical plastics are advanced polymer materials specifically engineered to meet stringent requirements for medical applications. These materials exhibit exceptional strength, durability, and biocompatibility, making them ideal for use in medical devices, implants, and surgical instruments. High-performance medical plastics offer properties such as resistance to sterilization methods, compatibility with various bodily fluids, and precision molding capabilities, enabling the creation of intricate and reliable medical devices.

According to the WHO 2021, around 1.3 million people die each year due to road traffic crashes and around 20 to 50 million more people suffer non-fatal injuries, with many experiencing a disability due to their injury.

Market Dynamics:

Driver:

Increasing awareness about environmental sustainability

With increasing awareness about the ecological repercussions of traditional plastics, industries, including healthcare, are pivoting towards sustainable alternatives. High performance medical plastics, renowned for their durability, biocompatibility, and sterilization capabilities, are witnessing a surge in adoption. These materials offer a compelling solution, aligning with the healthcare sector's stringent quality and safety standards while minimizing environmental impact. Manufacturers are investing in research and development to enhance the sustainability profile of these plastics further, catalyzing market growth.

Restraint:

Risk of material failure

The risk of material failure poses a significant challenge to the advancement of High Performance Medical Plastics (HPMP). These materials are crucial in various medical applications due to their superior properties like biocompatibility, durability, and resistance to chemicals. Ensuring their reliability under the demanding conditions of medical use is essential. However, material failures can lead to compromised performance, potential harm to patients, and increased costs for manufacturers. Factors such as long-term exposure to harsh chemicals, repeated sterilization processes, and mechanical stresses during use contribute to the risk of failure.

Opportunity:

Development of patient specific implants

The development of patient-specific implants has been a significant driving force behind the rise of high-performance medical plastics. These implants are tailored to individual patients' anatomical specifications, offering better compatibility and performance compared to traditional, one-size-fits-all implants. High-performance medical plastics play a crucial role in this customization process due to their versatility, biocompatibility, and durability. These materials can be precisely engineered to mimic the properties of human tissues, ensuring optimal integration within the body while providing necessary structural support. Additionally, they offer advantages such as lightweight design, resistance to corrosion, and flexibility, making them ideal for a wide range of medical applications.

Threat:

Cost constraints

Cost constraints pose a significant hindrance to the advancement of high-performance medical plastics. These materials often require specialized formulations and production processes to meet stringent safety and performance standards demanded by the medical industry. Achieving these standards while keeping costs low presents a considerable challenge. High-quality raw materials, precise manufacturing techniques, and rigorous quality control measures all contribute to elevated production expenses. As a result, the development and adoption of innovative medical plastics with superior performance characteristics may be limited by the need to balance affordability with functionality.

Covid-19 Impact:

The Covid-19 pandemic has significantly impacted the High Performance Medical Plastics market due to the surge in demand for medical equipment such as ventilators, face shields, and medical packaging has boosted the demand for high-performance medical plastics used in their manufacturing. However, disruptions in the global supply chain due to lockdowns and restrictions have led to challenges in sourcing raw materials and hindered production capacities. Overall, while the pandemic has posed challenges, it has also accelerated innovation and highlighted the critical role of high-performance medical plastics in healthcare applications.

The Polysulfone segment is expected to be the largest during the forecast period

Polysulfone segment is expected to be the largest during the forecast period. Polysulfone, a high-performance thermoplastic, is revolutionizing the medical plastics market due to its exceptional properties. Its superior strength, chemical resistance, and biocompatibility make it ideal for various medical applications. In medical devices, such as surgical instruments, catheters, and hemodialysis membranes, polysulfone offers unmatched durability and reliability. Its ability to withstand repeated sterilization cycles without degradation ensures product longevity and safety, crucial in healthcare settings.

The Drug Delivery segment is expected to have the highest CAGR during the forecast period

Drug Delivery segment is expected to have the highest CAGR during the forecast period. High performance medical plastics, known for their biocompatibility, durability, and versatility, serve as ideal materials for drug delivery systems. These plastics can be precisely engineered to encapsulate and deliver pharmaceuticals with increased efficiency and accuracy. Moreover, they enable targeted drug delivery, minimizing systemic side effects and improving patient outcomes. Advanced manufacturing techniques allow for the production of intricate drug delivery devices, such as implants, microspheres, and patches, tailored to specific therapeutic needs.

Region with largest share:

North America region commanded the largest share of the market during the extrapolated period, as medical devices are increasingly incorporating plastic components due to their versatility, lightweight nature, and cost-effectiveness compared to traditional materials like metal or glass. The advancements in medical technology require materials that can meet stringent regulatory standards while offering superior performance characteristics such as biocompatibility, durability, and resistance to sterilization processes. Furthermore, high-performance medical plastics fulfill these criteria, making them indispensable in the production of various medical devices ranging from catheters to surgical instruments.

Region with highest CAGR:

Asia Pacific region is estimated to witness robust growth over the projection time frame. Stringent regulations mandating the use of safe and high-quality materials in medical devices and equipment are prompting manufacturers to opt for advanced medical-grade plastics. These regulations ensure that medical devices meet strict safety and performance standards, driving the demand for high-performance medical plastics in the region. Regulatory initiatives focused on reducing healthcare-associated infections are spurring the adoption of antimicrobial and sterilizable plastics in medical applications.

Key players in the market

Some of the key players in High Performance Medical Plastics market include BASF SE, Bayer AG, DuPont, Eastman Chemical Company, Evonik Industries AG, Lubrizol Corporation, Mitsubishi Chemical Corporation, Raumedic AG, Rochling SE & Co. KG, Saint-Gobain Performance Plastic, The Chemours Company and Victrex PLC.

Key Developments:

In March2024, Evonik Industries AG and Vland Biotech Begin Joint Venture. The venture aims to expand the market presence of their livestock probiotics in Greater China and develop new products. Evonik's biotech platform is dedicated to creating biosolutions for healthier living. It innovates at the crossroads of chemistry, biotechnology, pharmacology, and data science.

In June2023, The Lubrizol Corporation will invest over $150 million (about ₹1,200 crore) across different projects in India. According to the specialty chemicals maker, the investments will be made into setting up CPVC (chlorinated polyvinyl chloride) resin plant in Vilayat, doubling the capacity at its site in Dahej in Gujarat and opening a grease lab in Navi Mumbai.

Raw Materials Covered:

• Polysulfone
• Polypropylene
• Polycarbonate
• Polyphenylene Sulfide
• Other Raw Materials

Applications Covered:

• Drug Delivery
• Prosthetics & Implants
• Medical Equipment & Tools
• Medical Disposables
• Other Applications

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Application Analysis
• 3.7 Emerging Markets
• 3.8 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global High Performance Medical Plastics Market, By Raw Material

• 5.1 Introduction
• 5.2 Polysulfone
• 5.3 Polypropylene
• 5.4 Polycarbonate
• 5.5 Polyphenylene Sulfide
• 5.6 Other Raw Materials

6 Global High Performance Medical Plastics Market, By Application

• 6.1 Introduction
• 6.2 Drug Delivery
• 6.3 Prosthetics & Implants
• 6.4 Medical Equipment & Tools
• 6.5 Medical Disposables
• 6.6 Other Applications

7 Global High Performance Medical Plastics Market, By Geography

• 7.1 Introduction
• 7.2 North America
  • 7.2.1 US
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 UK
  • 7.3.3 Italy
  • 7.3.4 France
  • 7.3.5 Spain
  • 7.3.6 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 Japan
  • 7.4.2 China
  • 7.4.3 India
  • 7.4.4 Australia
  • 7.4.5 New Zealand
  • 7.4.6 South Korea
  • 7.4.7 Rest of Asia Pacific
• 7.5 South America
  • 7.5.1 Argentina
  • 7.5.2 Brazil
  • 7.5.3 Chile
  • 7.5.4 Rest of South America
• 7.6 Middle East & Africa
  • 7.6.1 Saudi Arabia
  • 7.6.2 UAE
  • 7.6.3 Qatar
  • 7.6.4 South Africa
  • 7.6.5 Rest of Middle East & Africa

8 Key Developments

• 8.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 8.2 Acquisitions & Mergers
• 8.3 New Product Launch
• 8.4 Expansions
• 8.5 Other Key Strategies

9 Company Profiling

• 9.1 BASF SE
• 9.2 Bayer AG
• 9.3 DuPont
• 9.4 Eastman Chemical Company
• 9.5 Evonik Industries AG
• 9.6 Lubrizol Corporation
• 9.7 Mitsubishi Chemical Corporation
• 9.8 Raumedic AG
• 9.9 Rochling SE & Co. KG
• 9.10 Saint-Gobain Performance Plastic
• 9.11 The Chemours Company
• 9.12 Victrex PLC